Actavis today announced that it has received approval from the US Food & Drug Administration to market Carvedilol tablets in the US. Distribution of the product will commence immediately.

Carvedilol tablets, the generic equivalent of GlaxoSmithKline’s Coreg® tablets, will be available in 3.125, 6.25, 12.5 and 25 mg strength. Carvedilol tablets are indicated for the treatment of left ventricular dysfunction following myocardial infarction and for the management of essential hypertension.

Annual sales of Carvedilol tablets in the US were approximately US$1.7 billion for the twelve months ending June 2007 according to IMS Health data.

More information about Actavis in the US can be found at www.actavis.us